Extended Data Fig. 9: MALT1 ASO treatment leads to PD-L1 suppression and M1-like macrophage polarization in vitro.
a-b, Quantification of the survival rates of DMSO-treated, MI-2-treated, Mepazine-treated, and Thioridazine-treated E0771 (a) and B16F10 (b) cancer cells in co-culture system (- MΦ group) and in tri-culture system ( + MΦ group). The ratio of cancer cells, macrophages and T cells is 1: 2: 2. For a, n = 5 biological independent samples in DMSO + MΦ and MI-2 + MΦ group, and n = 6 biological independent samples in other groups. For b, n = 5 biological independent samples per group. Data represent mean ± SD. c, Quantification of cancer cell survival rates of ASONT, -24, or -25 treated B16F10 cancer cells in co-culture (- MΦ group) and in tri-culture system ( + MΦ group). The ratio of cancer cells, macrophages and T cells is 1: 2: 2. n = 6 biological independent samples. Data represent mean ± SD. d, Quantification of the cell number of BMDMs cultured with CM collected from ASO-treated B16F10 cells. n = 4 biological independent samples. Data represent mean ± SD. e-f, MFI of MHC-II (e) and CD206 (f) expression on macrophages cultured with CM collected from ASONT, -24, or -25 treated B16F10 cancer cells in vitro. n = 3 biological independent samples. Data represent mean ± SD. g-i, ELISA analyses of CSF1 (g), PGE2 (h), and CXCL1(i) levels in CM collected from ASONT and ASO24 treated E0771 cancer cells. Data represent mean ± SD. j-l. ELISA analyses of CSF1 (j), PGE2 (k), and CXCL1(l) levels in CM collected from ASONT and ASO24-treated B16F10 cancer cells. Data represent mean ± SD. m-o, The relative mRNA levels of Csf1 (m), Ptges (n), and Cxcl1 (o) in ASONT and ASO24-treated 4T1 cells. Data represent mean ± SD. p-r, The relative mRNA levels of Csf1 (p), Ptges (q), and Cxcl1 (r) in ASONT and ASO24-treated MC38 cells. Data represent mean ± SD. For g-r, n = 3 biological independent samples. For a-f, one-way ANOVA with Dunnett’s multiple comparisons test; for g-r, unpaired two-tailed t-test.
